This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
A neuropharmaceutical company committed to helping accelerate the development of effective therapeutic treatments for mental health disorders.
Founded in 2015, Small Pharma was established to identify promising innovative treatment options for depression and other mental health conditions.
Stock Performance
Small Pharma News 74 articles
- Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
- Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
- Enveric Biosciences CEO Issues Letter to Shareholders
- Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
- Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
- Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
- Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
- Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
- Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
- Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
- Small Pharma Reports Fiscal Second Quarter 2024 Highlights
- Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
- Disposition of Common Shares of Small Pharma Inc.
- Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
- Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
- Cybin to Acquire Small Pharma Inc.
- Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock
- Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB)
- Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
- Small Pharma Reports Fiscal First Quarter 2024 Highlights
- Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023
- Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023
- Small Pharma Announces Management Team Change
- Small Pharma Announces SPL028 R&D Strategy Update
- Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
- Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
- Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
- Small Pharma Announces Significant Developments In Intellectual Property Portfolio
- Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
- Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
- Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
- Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
- First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
- Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
- Small Pharma Reports Fiscal Third Quarter 2023 Highlights
- Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
- Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
- First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
- Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
- First Patient Dosed in Small Pharma’s Drug Interaction Study
Showing the 40 most recent of 74 articles.